HYFT ipatherapeutics.com: Company Value to Revenue Ratio

Public company logo of MindWalk Holdings Inc. (HYFT)

MindWalk Holdings (HYFT) is struggling in an aggressive environment against tech giants integrating AI into the cloud. The Enterprise Value to revenue ratio confirms valuation volatility, where 2988.91 expresses the latest level of the metric. Prospects depend on the implementation of BioStrand and B2B subscriptions, although the lack of stable cash flow and reliance on predictive contracts create temporary financial inertia.

HYFT: MindWalk Holdings Company Value to Revenue 11/23/2025 - 11/20/2026

HYFT (MindWalk): analytical breakdowns and indicator data

- market price and analyst price targets:
- company stock capitalization data:
- money and cash flow information:
Initial company analysis:HYFT - MindWalk Holdings Inc.
Mass-produced product of MindWalk Holdings, Inc.

The digital scalability of the MindWalk Holdings (HYFT) AI platform allows for the growth of licensing revenue without capital expenditures, making the business valuation relative to sales highly representative. This indicator compares the enterprise value (EV) to annual turnover, stripping the valuation of the influence of debt loads and subsidies; therefore, the EV-to-revenue trend on this chart reflects the real market value of each unit of income.

Direct competitors

HLN: Enterprise Value-to-Revenue Ratio|Kenvue Corp (KVUE) - Enterprise Value-to-Revenue Ratio|Verona Pharma PLC - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Jyong Biotech Ltd|EV/Sales Multiple Ligand Corp|EV/Sales Multiple AMRX|Total Company Value-to-Revenue Ratio Perrigo Company plc|EV/Sales Multiple ALVO (Alvotech Biopharmaceuticals)|LQDA: Company Value to Revenue Ratio|Galapagos N.V. - EV/Sales Multiple|ANIP - EV/Sales Multiple|MNKD: EV/Sales Multiple|amphastar.com (AMPH) - EV/Sales Multiple|PCRX (Pacira Pharmaceuticals) - EV/Sales Multiple|Company Value to Revenue ARS Pharmaceuticals, Inc. (SPRY)|EV/Sales Multiple TBPH|AQST (Aquestive Therapeutics) - Business Value to Revenue|scPharmaceuticals, Inc. - Company Value to Revenue|Business Value to Revenue TECX|tonixpharma.com - EV/Sales Multiple|Business Value to Revenue SXTC (sxtchina.com)|Eupraxia Pharma (EPRX) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue BioHarvest|Company Value to Revenue EXOZ|Company Value to Revenue Oramed Pharmaceuticals (ORMP)|Company Value to Revenue ENTX (Entera Bio Corp)|EV/Sales Multiple ABVC BioPharma, Inc. (ABVC)|Enterprise Value-to-Revenue Ratio Cumberland Corp CPIX|QNTM - Company Value to Revenue|FGEN - Enterprise Value-to-Revenue Ratio|TELO - EV/Sales Multiple|Rani Therapeutics Inc (RANI) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio SNYR|Enterprise Value-to-Revenue Ratio Rallybio Corp|Enterprise Value-to-Revenue Ratio LEXX|EV/Sales Multiple PULM|PTHL: Enterprise Value to Sales Volume|EV/Sales Multiple APM (Aptorum Group Ltd)|LYRA - Company Value to Revenue|Impact BioMedical Inc - EV/Sales Multiple|Enterprise Value to Sales Volume TNFA|YCBD (cbdmd.com) - Company Value to Revenue|painreform.com - Business Value to Revenue|Company Value to Revenue CYTO|Enterprise Value-to-Revenue Ratio LIPO|Enterprise Value-to-Revenue Ratio optinose.com (OPTN)|PIRS (Pieris Pharma) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Procaps Group S.A. PROC|Total Company Value-to-Revenue Ratio petrospharma.com (PTPI)|QLI - Enterprise Value-to-Revenue Ratio|Business Value to Revenue SLRN (ACELYRIN)|TFF Pharmaceuticals, Inc (TFFP) - Enterprise Value-to-Revenue Ratio